Styrelse

This section provides the financial market, owners and other interested parties with correct, relevant and timely information about our business and our performance. Investor information is released in Swedish for regulatory reasons and translated into English on a report-to-report basis. Please contact Redsense for additional information.

Bo Unéus

Bo Unéus

Chair of the Board

Elected Chairman: 2017 (elected as Board Member 2014)

Previous positions: Bo Unéus is also board member in CS Medica A/S. He has held senior positions at Nordstjernan and Skåne-Gripen and worked for many years on an international level. Worked with change processes for larger companies and groups, including Fiat in Turin. Sales manager at BTS, Celemi, Skåne-Gripen AB.

Shareholding: 26,500 shares and 72,463 stock options

Bo Unéus is independent of the Company and its management.

Susanne Olauson

Susanne Olauson

Member of the Board

Elected: 2013

Previous positions: Susanne Olauson is currently the CEO of Odinwell AB. She has twenty years of sales experience in the pharmaceutical industry, the medical technology industry and life science. Has held positions as VP Commercial Operations, European Congress Manager, Director Sales & Marketing development, product specialist and product manager in medical technology and pharma.

Shareholding: 72,463 stock options

Jörgen Hegbrant

Jörgen Hegbrant

Member of the Board

Elected: 2017

Previous positions: Jörgen Hegbrant, MD, PhD, is an Associate Professor in Nephrology at Lund University, Lund, Sweden. He has 35+ years of working experience in the field of nephrology and internal medicine, with 25 years of experience in senior positions in global companies in the dialysis business. Jörgen served as Senior Vice President & Chief Medical Officer (2007 – August 2019) at Diaverum AB, a global renal service provider operating dialysis clinic in 20+ countries. Prior to Diaverum, he held leading positions in Gambro AB as Chief Medical Officer at Gambro Healthcare International and Senior Medical Director at Corporate Research, Gambro AB. Jörgen has global knowledge in the area of chronic kidney disease and dialysis, with broad experience from academia, research & development, dialysis clinic operations and healthcare management. Currently Jörgen is CEO & Chief Medical Officer at JBA Medical AB, furthermore, he serves as Senior Medical Advisor & Board Observer at Triomed AB, Senior Medical Advisor at LundaTec AB and as Advisor at Medicalisys Ltd.

Shareholding: 8,186 shares and 72,463 stock options.

Jörgen Hegbrant is independent of the Company and its management.

Maria Alquist

Maria Alquist

Member of the Board

Elected: 2019

Previous positions: Has held leading positions as VP Global Medical & Scientific, Senior Medical Director Research and Medical Safety at Gambro. Has extensive experience within global kidney care and dialysis companies. Serves as an expert in assessment committees within the Medtech area of the Foundation for Strategic Research, which annually awards around SEK 600 million to strategic research in the natural sciences, technology and medicine.

Shareholding: 2,000 shares and 72,463 stock options

Maria Alquist is independent of the Company and its management.

Annette Colin

Annette Colin

Member of the Board

Elected: 2021

Previous positions: Annette Colin has more than 25 years of experience in executive positions such as CEO, CFO, COO, Group Financial Controller and Tax Manager, including 15 years in Life Science.  Annette has been part of fast-growing companies and organizations and has broad finance skills and long experience in, among other things, building strategic planning, raising capital, business development, leadership development, streamlining infrastructure and Investor Relations. She has been involved in several M&A and IPO transactions and worked with both Venture Capital, Private Equity owners and the majority in Publicly listed companies, from start-ups to Large Cap companies.

Most recent assignments include Annexin Pharmaceuticals AB (publ) Observe Medical International (publ), Stille AB (publ), Lindab International AB (publ), Perbio Science AB (publ) and EY. She is currently board member of Initiator Pharma A/S and Sozap AB (publ). Today Annette is Group CFO and responsible for IR at Biotage AB (publ). She has education in Business Administration and law at Lund University, Sweden.

Shareholding: 2640

Annette Colin is independent of the Company and its management.